Genmab stopped enrollment in an early‑stage Phase 1/2 study of GEN1286, a cancer candidate acquired through its $1.8 billion buyout of ProfoundBio. The study had targeted roughly 260 patients; the hold on enrollment signals an immediate development pause and raises questions about the program’s regulatory and clinical pathway. Genmab’s decision will affect timelines for the molecule’s evaluation and may influence integration plans following the ProfoundBio acquisition as the company reassesses safety, enrollment feasibility or strategic fit.